MX340669B - Formas farmaceuticas para compuestos debilmente ionizables. - Google Patents

Formas farmaceuticas para compuestos debilmente ionizables.

Info

Publication number
MX340669B
MX340669B MX2011002084A MX2011002084A MX340669B MX 340669 B MX340669 B MX 340669B MX 2011002084 A MX2011002084 A MX 2011002084A MX 2011002084 A MX2011002084 A MX 2011002084A MX 340669 B MX340669 B MX 340669B
Authority
MX
Mexico
Prior art keywords
dosage forms
weakly ionizable
drug
ionizable compounds
self
Prior art date
Application number
MX2011002084A
Other languages
English (en)
Other versions
MX2011002084A (es
Inventor
Agarwal Vikas
M Nazzal Sami
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of MX2011002084A publication Critical patent/MX2011002084A/es
Publication of MX340669B publication Critical patent/MX340669B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción se refiere a formas farmacéuticas (p. ej., formas farmacéuticas sólidas) que comprenden una emulsión que contiene un fármaco, una microemulsión que contiene un fármaco, una composición oleosa autoemulsionante o una composición oleosa automicroemulsionante, donde cada una comprende un fármaco débilmente ionizable y un modificador del pH. También se proporcionan formas farmacéuticas (p. ej., formas farmacéuticas solidas) y los métodos para prepararlas.
MX2011002084A 2008-09-09 2009-09-09 Formas farmaceuticas para compuestos debilmente ionizables. MX340669B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9549308P 2008-09-09 2008-09-09
US16199209P 2009-03-20 2009-03-20
PCT/US2009/056362 WO2010030667A2 (en) 2008-09-09 2009-09-09 Dosage forms for weakly ionizable compounds

Publications (2)

Publication Number Publication Date
MX2011002084A MX2011002084A (es) 2011-03-29
MX340669B true MX340669B (es) 2016-07-20

Family

ID=41667166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011002084A MX340669B (es) 2008-09-09 2009-09-09 Formas farmaceuticas para compuestos debilmente ionizables.

Country Status (5)

Country Link
EP (1) EP2334302B1 (es)
JP (1) JP5661630B2 (es)
CA (1) CA2735660C (es)
MX (1) MX340669B (es)
WO (1) WO2010030667A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884039B2 (en) * 2013-04-05 2018-02-06 Scpharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
CN108295264A (zh) * 2018-03-28 2018-07-20 五邑大学 聚乙烯吡咯烷酮k12的应用
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
WO2020141224A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
AU2020214314B2 (en) 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613332B1 (en) * 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6280770B1 (en) * 1998-08-13 2001-08-28 Cima Labs Inc. Microemulsions as solid dosage forms for oral administration
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
AU1548001A (en) * 1999-11-24 2001-06-04 Wakamoto Pharmaceutical Co., Ltd. Ophthalmic aqueous preparation
JP5684440B2 (ja) * 2001-02-23 2015-03-11 シーマ・ラブス、インコーポレイテッド 組成物および固形製剤
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin

Also Published As

Publication number Publication date
JP2012502065A (ja) 2012-01-26
WO2010030667A3 (en) 2010-07-22
CA2735660C (en) 2017-05-30
CA2735660A1 (en) 2010-03-18
EP2334302B1 (en) 2018-03-21
JP5661630B2 (ja) 2015-01-28
MX2011002084A (es) 2011-03-29
WO2010030667A2 (en) 2010-03-18
EP2334302A2 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
EA025302B8 (ru) Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201100032A1 (ru) Соединения пиридина
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
TW200716646A (en) (S)-N-methylnaltrexone
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
GEP20146060B (en) Pyridyl inhibitors of hedgehog signalling
WO2009121039A3 (en) Administration of benzodiazepine compositions
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
EA201170772A1 (ru) Органические соединения
EA201290138A1 (ru) Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
TN2012000347A1 (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
MX340669B (es) Formas farmaceuticas para compuestos debilmente ionizables.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
JO2645B1 (en) Vehicles
AU2012347200A8 (en) Tablet capable of combatting misuse by injection
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола

Legal Events

Date Code Title Description
FG Grant or registration